In this study, we have exploited this higher-affinity ligand, PSMA-1 [43], to selectively deliver the very potent microtubule disruption drug, monomethyl auristatin E (MMAE), to prostate cancer cells. Here, PSMA1 is linked to prostate carcinoma.